Paper35118917
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis.
Wen W and 11 others. Ann Med, 2022. Cited by 307 papers, by iCite.
Cite this record
ConductScience Library. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis. Papers, record 35118917. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35118917
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Fluvoxamine | Major topic |
| COVID-19 Drug Treatment | Major topic |
| Antiviral Agents | |
| Cytidine | |
| Drug Combinations | |
| Humans | |
| Hydroxylamines | |
| Lactams | |
| Leucine | |
| Nitriles | |
| Proline | |
| Ritonavir | |
| SARS-CoV-2 |
Source PubMed
References27
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33180097 | Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. | JAMA | 2020 | https://conductscience.org/library/papers/33180097 | PubMed |
| 2 | 33743213 | Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. | Cell | 2021 | https://conductscience.org/library/papers/33743213 | PubMed |
| 3 | 31578288 | Small-Molecule Antiviral β-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance. | J Virol | 2019 | https://conductscience.org/library/papers/31578288 | PubMed |
| 4 | 32321732 | Remdesivir in covid-19. | BMJ | 2020 | https://conductscience.org/library/papers/32321732 | PubMed |
| 5 | 33649113 | Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2. | Antimicrob Agents Chemother | 2021 | https://conductscience.org/library/papers/33649113 | PubMed |
| 6 | 32253226 | An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. | Sci Transl Med | 2020 | https://conductscience.org/library/papers/32253226 | PubMed |
| 7 | 33959018 | Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/33959018 | PubMed |
| 8 | 33863887 | Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. | Nat Commun | 2021 | https://conductscience.org/library/papers/33863887 | PubMed |
| 9 | 34754175 | What will be the role of molnupiravir in the treatment of COVID-19 infection? | Drugs Ther Perspect | 2021 | https://conductscience.org/library/papers/34754175 | PubMed |
| 10 | 34066475 | Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. | Vaccines (Basel) | 2021 | https://conductscience.org/library/papers/34066475 | PubMed |
| 11 | 35186365 | Childhood Immunization Schedule for National Immunization Program Vaccines - China (Version 2021). | China CDC Wkly | 2021 | https://conductscience.org/library/papers/35186365 | PubMed |
| 12 | 34717820 | Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. | Lancet Glob Health | 2022 | https://conductscience.org/library/papers/34717820 | PubMed |
| 13 | 34607801 | Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. | BMJ | 2021 | https://conductscience.org/library/papers/34607801 | PubMed |
| 14 | 34641339 | Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19. | Molecules | 2021 | https://conductscience.org/library/papers/34641339 | PubMed |
| 15 | 33623808 | Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19. | Open Forum Infect Dis | 2021 | https://conductscience.org/library/papers/33623808 | PubMed |
| 16 | 33961695 | β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. | J Infect Dis | 2021 | https://conductscience.org/library/papers/33961695 | PubMed |
| 17 | 34381216 | Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. | Nat Struct Mol Biol | 2021 | https://conductscience.org/library/papers/34381216 | PubMed |
| 18 | 33654292 | SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. | Nat Med | 2021 | https://conductscience.org/library/papers/33654292 | PubMed |
| 19 | 33688914 | CDC Interim Recommendations for Fully Vaccinated People: An Important First Step. | JAMA | 2021 | https://conductscience.org/library/papers/33688914 | PubMed |
| 20 | 34118236 | Decoding molnupiravir-induced mutagenesis in SARS-CoV-2. | J Biol Chem | 2021 | https://conductscience.org/library/papers/34118236 | PubMed |
Cited by231
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 307 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42653319 | The Combination of Nirmatrelvir and Ivermectin Exerts Strongly Synergistic Antiviral and Anti-Inflammatory Effects Against Murine Coronavirus Infection of Macrophages. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42653319 | PubMed |
| 42353136 | Dual-Action Niclosamide-Polysaccharide Nasal Spray for the Early Therapeutic Intervention of Respiratory Viral Infections. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42353136 | PubMed |
| 42326460 | Nirmatrelvir-Ritonavir-Induced Pancreatitis: A Concern in the COVID Era. | ACG Case Rep J | 2026 | https://conductscience.org/library/papers/42326460 | PubMed |
| 41904401 | CD4 T-cell platform for delivering interferons as an antiviral countermeasure with a focus on SARS-CoV-2. | Mol Med | 2026 | https://conductscience.org/library/papers/41904401 | PubMed |
| 41868151 | Based a machine learning approach to investigate the factors influencing nirmatrelvir/ritonavir exposure in human plasma: a multicenter, observational study. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/41868151 | PubMed |
| 41788322 | Effectiveness of Nirmatrelvir/Ritonavir in Unvaccinated COVID-19 Patients Treated in the Emergency Department: A Retrospective Propensity-Matched Cohort Analysis. | Ther Adv Pulm Crit Care Med | 2026 | https://conductscience.org/library/papers/41788322 | PubMed |
| 41676148 | Autophagy in emerging and highly concerned severe zoonotic infectious diseases. | Front Immunol | 2026 | https://conductscience.org/library/papers/41676148 | PubMed |
| 41382264 | Effectiveness comparison of nirmatrelvir/ritonavir versus molnupiravir in COVID-19 patients with comorbidities in Taiwan: a multi-centre electronic health record study. | BMC Infect Dis | 2025 | https://conductscience.org/library/papers/41382264 | PubMed |
| 41327284 | CfDNA as a surrogate marker for COVID-19 severity in patients with influenza-like symptoms with and without SARS-CoV-2 infection in general practice: a prospective cohort study. | Virol J | 2025 | https://conductscience.org/library/papers/41327284 | PubMed |
| 41200312 | Molecular and pathological confirmation of natural feline coronavirus infection in a captive persian leopard (Panthera pardus tulliana): Implications for Wildlife conservation and one health. | Open Vet J | 2025 | https://conductscience.org/library/papers/41200312 | PubMed |
| 41093342 | Quality and readability of drug fact sheets for FDA-approved and emergency use authorised drug products for COVID-19 treatment: an observational study. | BMJ Open | 2025 | https://conductscience.org/library/papers/41093342 | PubMed |
| 41004466 | Paxlovid plus glucocorticoids treatment in severe Omicron infected patients with hypoxaemia: A prospective multiple-center cohort study. | PLoS One | 2025 | https://conductscience.org/library/papers/41004466 | PubMed |
| 40879599 | A laboratory-focussed desk review of health systems in Uganda, Kenya, and the UK to respond to current and future pandemics. | J Glob Health | 2025 | https://conductscience.org/library/papers/40879599 | PubMed |
| 40864723 | Broad-spectrum synthetic carbohydrate receptors (SCRs) inhibit viral entry across multiple virus families. | Sci Adv | 2025 | https://conductscience.org/library/papers/40864723 | PubMed |
| 40861788 | Factors Influencing COVID-19 Viral Clearance: Implications for Vaccination and Antiviral Therapy. | Infect Drug Resist | 2025 | https://conductscience.org/library/papers/40861788 | PubMed |
| 40802235 | Design, synthesis and SARS-CoV‑2 main protease inhibitory activities of 2-arylthiomethyl-6-bromoindole derivatives. | Mol Divers | 2026 | https://conductscience.org/library/papers/40802235 | PubMed |
| 40741617 | Multitarget-based in silico screening from phytoactive compounds of Garcinia linii fighting toward severe acute respiratory syndrome coronavirus-2. | Tzu Chi Med J | 2025 | https://conductscience.org/library/papers/40741617 | PubMed |
| 40732341 | Supercomputing Multi-Ligand Modeling, Simulation, Wavelet Analysis and Surface Plasmon Resonance to Develop Novel Combination Drugs: A Case Study of Arbidol and Baicalein Against Main Protease of SARS-CoV-2. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40732341 | PubMed |
| 40437072 | Sulfonohydrazide as a potential inhibitor of SARS-CoV-2 infection. | Sci Rep | 2025 | https://conductscience.org/library/papers/40437072 | PubMed |
| 40376119 | Patient Experiences With Nirmatrelvir/Ritonavir for COVID-19 in a Collaborative Care Model: A Cross-Sectional Study on Self-Management, Information, and Medication Impact. | J Patient Exp | 2025 | https://conductscience.org/library/papers/40376119 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TMBIM4 | 51643 | PubTator's text mining | https://conductscience.org/library/genes/51643 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35118917
GET https://conductscience.org/api/papers/v1/35118917/references?page=2